BioMarin Pharmaceutical Inc.

BMRN·NasdaqGS
Compare
55.39+0.60 (+1.09%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours55.62+0.23 (+0.42%)Oct 12, 7:12 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close54.80
Open55.00
Day range54.9955.96
52-week range49.2670.98
Off day high−1.02%
Off 52-week high−21.96%
Volume2.36M
Avg. volume (3M)2.07M
Market cap10.72B
EPS (TTM)0.3700
Forward P/E8.35
P/E ratio (TTM)149.70
Dividend yield—
Beta (5Y)—
Shares outstanding193.57M
Short interest—
Earnings dateAug 6, 2026
Analyst target—
Profit margin—

Against its peers

Compare in full ›
BMRN BBIO IONS KRYS RARE LGND
Market cap 10.72B 12.85B 7.26B 9.83B 1.51B 6.20B
P/E (TTM) 149.7 — — 41.6 — 32.8
Forward P/E 8.3 2,275.1 -39.3 35.8 25.8 26.0
Price/book 1.7 -5.1 16.4 7.2 -5.2 6.4
Dividend yield — — — — — —
1-year change +5.57% +16.37% −35.85% +79.50% −51.66% +67.77%
Today +1.09% +0.61% −3.56% +0.14% −1.16% +3.09%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All BMRN news ›
24/7 Wall St.·Positive

Biomarin Pharmaceutical Inc

Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets → BioMarin appears attractively valued at current levels. With a 13.7% upside to…

@PRNewswire·Positive

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

Shares of biotech company BioMarin Pharmaceutical (NASDAQ: BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alesta Therapeutics, a clinical-stage biotech company. According to a company press release, BioMarin…

TipRanks Financial·Negative

BioMarin Stock Slips As Pipeline Hype Fails To Impress

BioMarin Pharmaceutical ( (BMRN) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement. For longer-term investors, BioMarin’s strong revenue growth, raised guidance, and healthy cash generation…

Stock Titan·Positive

Sweetgreen Announces Lauren Crowley as Chief People Officer

Sweetgreen (NYSE: SG) appointed Lauren Crowley as Chief People Officer, effective October 26, 2026, reporting directly to CEO Jonathan Neman. LOS ANGELES--(BUSINESS WIRE)-- Sweetgreen, Inc. (NYSE: SG), the mission-driven restaurant brand…

note(ノート)·Positive

BioMarin Pharmaceutical | Science & Technology

BioMarin Pharmaceutical (2026) ‘BioMarin Announces New Three-Year VOXZOGO Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026’, BioMarin Pharmaceutical. BioMarin Pharmaceutical (2026) ‘BioMarin Provides Update on Phase 3 Trial…

The Globe and Mail·Negative

BioMarin Pharmaceutical Adds Independent Director to Board

An update from BioMarin Pharmaceutical ( (BMRN) ) is now available. On September 10, 2026, BioMarin Pharmaceutical Inc. expanded its Board of Directors from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as an independent…

From articles in the 4Search news index.

In the news

10mentions in 30 days
7with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.